Where does Alexander Schubert work?

Alexander Schubert is Partner at SciFounders.

What check size does Alexander Schubert write?

Alexander Schubert typically writes checks of $400K – $1M.

What companies has Alexander Schubert invested in?

Investments tracked here include Ditto Biosciences.

Where did Alexander Schubert go to school?

Alexander Schubert studied at University of Cambridge (Doctor of Philosophy (PhD), Molecular Biology).

What has Alexander Schubert written?

Alexander Schubert has 3 tracked posts on alexschubert.xyz, including "Is the Boring Backbone of Biopharma the Next Big AI Opportunity?", "Into the venom mines", "Why we have to pass on startups".

Alexander Schubert

Investor

Partner at SciFounders

San Francisco Bay Area

Writes $400K – $1M checks · typically $1.5M

Find your path to Alexander

310 people in our graph can introduce you to Alexander.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Matt Krisiloff to introduce you to Alexander

You →Matt · together at SciFounders (2021–2026) →Alexander

Ask Jamie Chen to introduce you to Alexander

You →Jamie · 2 people · together at SciFounders →Alexander

Ask Sam Okafor to introduce you to Alexander

You →Sam · 4 people · together at MRC Laboratory of Molecular Biology (LMB) →Alexander

Your email: the people you already email who know Alexander
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Alexander
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

Alexander Schubert is an early-stage deep tech investor focused on biotech and science-driven startups. He writes extensively about founder-led biotech, how research-intensive companies can be built with limited funding, and where AI can be applied across the biopharma value chain — from drug discovery to the document-heavy operational backbone of late-stage clinical development. His fund invests in a small fraction of the companies it evaluates, concentrating on early-stage deep tech. He is associated with SciFounders and works alongside teammate Matt Krisiloff.

Contact· published on Alexander's own website

alexander@scifounders.com

Invests in

AI & Machine LearningBiotechDeep TechHardwareHealthtechMedical Devices

Beyond investing

Communities: Works alongside teammate Matt Krisiloff at SciFounders.

From Alexander's own website — common ground for a warm intro.

Experience

SciFoundersPartner and Co-Foundercurrent2021 — presentSan Francisco Bay Area
GenentechIndependent Researcher2018 — 2021
MRC Laboratory of Molecular Biology (LMB)PhD Researcher2014 — 2018Greater Cambridge Area

Skills & more

Languages Deutsch · Englisch

Doctor of Philosophy — University of Cambridge

From Alexander's professional profile.

Investments

Investor

Ditto Biosciences

Per curated public sources.

Leave your own feedback

Writing

All posts ↗

Alexander Schubert writes about AI and biotech opportunities, covering LLM automation of late-stage clinical and regulatory workflows and computational venom mining for drug discovery, as well as how deep tech VCs evaluate early-stage startups.

Is the Boring Backbone of Biopharma the Next Big AI Opportunity?2026-05-12

The author argues that late-stage clinical development workflows like regulatory affairs, pharmacovigilance, clinical trial programming, and medical writing are underexplored, document-heavy areas well-suited for LLM automation despite high stakes and difficult sales.

Into the venom mines2025-09-11

The author contends that animal toxins are a vast untapped drug-discovery resource and that next-gen sequencing, LLMs, and molecular docking now make large-scale venom mining feasible and cost-effective.

Why we have to pass on startups2025-05-02

Drawing on notes from ~500 startups, the author outlines seven factors deep tech VCs evaluate, including differentiation, opportunity size, commercialization risk, founding team, communication, and science.

Colleagues at SciFounders

Lucas Harrington

Co-founder and CSO at SciFounders

Matt Krisiloff

CEO at SciFounders

Frequently asked questions

Who is Alexander Schubert?: Alexander Schubert is an early-stage deep tech investor focused on biotech and science-driven startups. He writes extensively about founder-led biotech, how research-intensive companies can be built with limited funding, and where AI can be applied across the biopharma value chain — from drug discovery to the document-heavy operational backbone of late-stage clinical development. His fund invests in a small fraction of the companies it evaluates, concentrating on early-stage deep tech. He is associated with SciFounders and works alongside teammate Matt Krisiloff.
Where does Alexander Schubert work?: Alexander Schubert is Partner at SciFounders.
What does Alexander Schubert invest in?: Alexander Schubert invests in AI & Machine Learning, Biotech, Deep Tech, Hardware, Healthtech, Medical Devices.
What check size does Alexander Schubert write?: Alexander Schubert typically writes checks of $400K – $1M.
What companies has Alexander Schubert invested in?: Investments tracked here include Ditto Biosciences.
Where did Alexander Schubert go to school?: Alexander Schubert studied at University of Cambridge (Doctor of Philosophy (PhD), Molecular Biology).
What has Alexander Schubert written?: Alexander Schubert has 3 tracked posts on alexschubert.xyz, including "Is the Boring Backbone of Biopharma the Next Big AI Opportunity?", "Into the venom mines", "Why we have to pass on startups".